Article
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
The Journal of infectious diseases - 15 Jun 2013
Tang Michele W, Rhee Soo-Yon, Bertagnolio Silvia, Ford Nathan, Holmes Susan, Sigaloff Kim C, Hamers Raph L, de Wit Tobias F Rinke, Fleury Herve J, Kanki Phyllis J, Ruxrungtham Kiat, Hawkins Claudia A, Wallis Carole L, Stevens Wendy, van Zyl Gert U, Manosuthi Weerawat, Hosseinipour Mina C, Ngo-Giang-Huong Nicole, Belec Laurent, Peeters Martine, Aghokeng Avelin, Bunupuradah Torsak, Burda Sherri, Cane Patricia, Cappelli Giulia, Charpentier Charlotte, Dagnra Anoumou Y, Deshpande Alaka K, El-Katib Ziad, Eshleman Susan H, Fokam Joseph, Gody Jean-Chrysostome, Katzenstein David, Koyalta Donato D, Kumwenda Johnstone J, Lallemant Marc, Lynen Lutgarde, Marconi Vincent C, Margot Nicolas A, Moussa Sandrine, Ndung'u Thumbi, Nyambi Phillipe N, Orrell Catherine, Schapiro Jonathan M, Schuurman Rob, Sirivichayakul Sunee, Smith Davey, Zolfo Maria, Jordan Michael R, Shafer Robert W
Abstract excerpt
BACKGROUND: The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available in resource-limited...
Read the complete abstract on PubMed